vimarsana.com

Page 102 - ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Coronavirus (COVID-19) Update: FDA Makes Two Revisions to Moderna COVID-19 Vaccine Emergency Use Authorization to Help Increase the Number of Vaccine Doses Available

Share this article Share this article SILVER SPRING, Md., April 1, 2021 /PRNewswire/ Today, the U.S. Food and Drug Administration announced two revisions regarding the number of doses per vial available for the Moderna COVID-19 Vaccine. The first revision clarifies the number of doses per vial for the vials that are currently available, in that the maximum number of extractable doses is 11, with a range of 10-11 doses. The second revision authorizes the availability of an additional multi-dose vial in which each vial contains a maximum of 15 doses, with a range of 13-15 doses that can potentially be extracted. Both of these revisions positively impact the supply of Moderna COVID-19 Vaccine, which will help provide more vaccine doses to communities and allow shots to get into arms more quickly. Ultimately, more vaccines getting to the public in a timely manner should help bring an end to the pandemic more rapidly, said Peter Marks, M.D., Ph.D., director of the FDA s Center for

Kelyniam Global Releases Annual 2020 Financials

Kelyniam Global Releases Annual 2020 Financials A Solid Year and Steady Growth despite Covid-19 News provided by Share this article Share this article CANTON, Conn., April 2, 2021 /PRNewswire/ Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its year ended December 31, 2020.  I am pleased to announce that Kelyniam returned to profitability in 2020, reaching a significant milestone in the third year of our five year plan.  Despite a 2 nd wave of elective surgery restrictions in the fourth quarter, Kelyniam, customers embraced our unique ability to reliably deliver custom, well designed implants overnight, said Ross Bjella, Kelyniam s CEO.   Our focus on specific markets and the increase in new surgeons (or facilities) using our products, along with - aggressive expense management in the last half of the year resulted in record Sales Revenue and Profitability.

Medical Engineered Materials Market worth $29 1 billion by 2025 - Exclusive Report by MarketsandMarkets™

Based on type, medical plastics is estimated to be the largest market in the overall medical engineered materials market in 2020. Medical plastics is the major largest segment amongst others in the market. Medical plastics are required in various applications in the healthcare field such as manufacturing of medical devices, tools, disposables, and diagnostic equipments which is responsible for the large market size. Growing healthcare infrastructure in emerging economies and increasing instances of chronic diseases are expected to drive the medical devices market, which, in turn, is likely to propel the demand for medical plastics. Based on application, medical disposables is expected to be the largest medical engineered materials consuming sector in 2020.

BD Receives Emergency Use Authorization for Asymptomatic Screening for SARS-CoV-2 through Serial Rapid Antigen Testing

Share this article Share this article FRANKLIN LAKES, N.J., April 1, 2021 /PRNewswire/  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its rapid antigen test to be used for SARS-CoV-2 screening through serial testing of asymptomatic individuals. BD today announced the FDA has granted Emergency Use Authorization (EUA) for its BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 to be used for SARS-CoV-2 screening through serial testing of asymptomatic individuals. An elementary school student is receives a rapid antigen test using the BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2.

Blister Packaging Market in the US to Grow by USD 1 56 Billion at Almost 9% CAGR During 2020-2024

Blister Packaging Market in US: Growing Pharmaceutical Industry The rising prevalence of various chronic diseases in the US has increased the demand for drugs. This is encouraging drug manufacturers to introduce newer drugs with improved efficacies. Besides, the market has witnessed a significant increase in the number of drug approvals by the FDA over the past few years. All these factors are contributing to the growth of the pharmaceutical industry in the US, which, in turn, is driving the market in focus. Growing unit-dose packaging and increased healthcare expenditure in the US will further boost market growth during the forecast period , says a senior analyst at Technavio.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.